These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 22695117)

  • 1. NF-κB signaling is activated and confers resistance to apoptosis in three-dimensionally cultured EGFR-mutant lung adenocarcinoma cells.
    Sakuma Y; Yamazaki Y; Nakamura Y; Yoshihara M; Matsukuma S; Koizume S; Miyagi Y
    Biochem Biophys Res Commun; 2012 Jul; 423(4):667-71. PubMed ID: 22695117
    [TBL] [Abstract][Full Text] [Related]  

  • 2. WZ4002, a third-generation EGFR inhibitor, can overcome anoikis resistance in EGFR-mutant lung adenocarcinomas more efficiently than Src inhibitors.
    Sakuma Y; Yamazaki Y; Nakamura Y; Yoshihara M; Matsukuma S; Nakayama H; Yokose T; Kameda Y; Koizume S; Miyagi Y
    Lab Invest; 2012 Mar; 92(3):371-83. PubMed ID: 22157722
    [TBL] [Abstract][Full Text] [Related]  

  • 3. NF-κB-activating complex engaged in response to EGFR oncogene inhibition drives tumor cell survival and residual disease in lung cancer.
    Blakely CM; Pazarentzos E; Olivas V; Asthana S; Yan JJ; Tan I; Hrustanovic G; Chan E; Lin L; Neel DS; Newton W; Bobb KL; Fouts TR; Meshulam J; Gubens MA; Jablons DM; Johnson JR; Bandyopadhyay S; Krogan NJ; Bivona TG
    Cell Rep; 2015 Apr; 11(1):98-110. PubMed ID: 25843712
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Suppressed expression of Cbl-b by NF-κB mediates icotinib resistance in EGFR-mutant non-small-cell lung cancer.
    Zhang T; Zheng C; Hou K; Wang J; Zhang Y; Fan Y; Zhao H; Qu X; Liu Y; Kang J; Che X; Hu X
    Cell Biol Int; 2019 Feb; 43(2):98-107. PubMed ID: 29972257
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enhanced YAP expression leads to EGFR TKI resistance in lung adenocarcinomas.
    Lee TF; Tseng YC; Nguyen PA; Li YC; Ho CC; Wu CW
    Sci Rep; 2018 Jan; 8(1):271. PubMed ID: 29321482
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Podoplanin-positive cancer-associated fibroblasts in the tumor microenvironment induce primary resistance to EGFR-TKIs in lung adenocarcinoma with EGFR mutation.
    Yoshida T; Ishii G; Goto K; Neri S; Hashimoto H; Yoh K; Niho S; Umemura S; Matsumoto S; Ohmatsu H; Iida S; Niimi A; Nagai K; Ohe Y; Ochiai A
    Clin Cancer Res; 2015 Feb; 21(3):642-51. PubMed ID: 25388165
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Picoliter-Droplet Digital Polymerase Chain Reaction-Based Analysis of Cell-Free Plasma DNA to Assess EGFR Mutations in Lung Adenocarcinoma That Confer Resistance to Tyrosine-Kinase Inhibitors.
    Seki Y; Fujiwara Y; Kohno T; Takai E; Sunami K; Goto Y; Horinouchi H; Kanda S; Nokihara H; Watanabe S; Ichikawa H; Yamamoto N; Kuwano K; Ohe Y
    Oncologist; 2016 Feb; 21(2):156-64. PubMed ID: 26768482
    [TBL] [Abstract][Full Text] [Related]  

  • 8. FAS and NF-κB signalling modulate dependence of lung cancers on mutant EGFR.
    Bivona TG; Hieronymus H; Parker J; Chang K; Taron M; Rosell R; Moonsamy P; Dahlman K; Miller VA; Costa C; Hannon G; Sawyers CL
    Nature; 2011 Mar; 471(7339):523-6. PubMed ID: 21430781
    [TBL] [Abstract][Full Text] [Related]  

  • 9. NF-κB drives acquired resistance to a novel mutant-selective EGFR inhibitor.
    Galvani E; Sun J; Leon LG; Sciarrillo R; Narayan RS; Sjin RT; Lee K; Ohashi K; Heideman DA; Alfieri RR; Heynen GJ; Bernards R; Smit EF; Pao W; Peters GJ; Giovannetti E
    Oncotarget; 2015 Dec; 6(40):42717-32. PubMed ID: 26015408
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metformin synergistically enhances the antitumor activity of the third-generation EGFR-TKI CO-1686 in lung cancer cells through suppressing NF-κB signaling.
    Pan YH; Lin CY; Lu CH; Li L; Wang YB; Chen HY; He Y
    Clin Respir J; 2018 Dec; 12(12):2642-2652. PubMed ID: 30307719
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prolyl isomerase Pin1 promotes survival in EGFR-mutant lung adenocarcinoma cells with an epithelial-mesenchymal transition phenotype.
    Sakuma Y; Nishikiori H; Hirai S; Yamaguchi M; Yamada G; Watanabe A; Hasegawa T; Kojima T; Niki T; Takahashi H
    Lab Invest; 2016 Apr; 96(4):391-8. PubMed ID: 26752745
    [TBL] [Abstract][Full Text] [Related]  

  • 12. NF-κB activation is an early event of changes in gene regulation for acquiring drug resistance in human adenocarcinoma PC-9 cells.
    Fukuoka M; Yoshioka K; Hohjoh H
    PLoS One; 2018; 13(8):e0201796. PubMed ID: 30075033
    [TBL] [Abstract][Full Text] [Related]  

  • 13. V843I, a lung cancer predisposing EGFR mutation, is responsible for resistance to EGFR tyrosine kinase inhibitors.
    Matsushima S; Ohtsuka K; Ohnishi H; Fujiwara M; Nakamura H; Morii T; Kishino T; Goto H; Watanabe T
    J Thorac Oncol; 2014 Sep; 9(9):1377-84. PubMed ID: 25057940
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination of BIBW2992 and ARQ 197 is effective against erlotinib-resistant human lung cancer cells with the EGFR T790M mutation.
    Qu G; Liu C; Sun B; Zhou C; Zhang Z; Wang P
    Oncol Rep; 2014 Jul; 32(1):341-7. PubMed ID: 24842595
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Progesterone receptor membrane component 1 leads to erlotinib resistance, initiating crosstalk of Wnt/β-catenin and NF-κB pathways, in lung adenocarcinoma cells.
    Lin Y; Higashisaka K; Shintani T; Maki A; Hanamuro S; Haga Y; Maeda S; Tsujino H; Nagano K; Fujio Y; Tsutsumi Y
    Sci Rep; 2020 Mar; 10(1):4748. PubMed ID: 32179851
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The combination of irreversible EGFR TKIs and SAHA induces apoptosis and autophagy-mediated cell death to overcome acquired resistance in EGFR T790M-mutated lung cancer.
    Lee TG; Jeong EH; Kim SY; Kim HR; Kim CH
    Int J Cancer; 2015 Jun; 136(11):2717-29. PubMed ID: 25382705
    [TBL] [Abstract][Full Text] [Related]  

  • 17. TPCA-1 is a direct dual inhibitor of STAT3 and NF-κB and regresses mutant EGFR-associated human non-small cell lung cancers.
    Nan J; Du Y; Chen X; Bai Q; Wang Y; Zhang X; Zhu N; Zhang J; Hou J; Wang Q; Yang J
    Mol Cancer Ther; 2014 Mar; 13(3):617-29. PubMed ID: 24401319
    [TBL] [Abstract][Full Text] [Related]  

  • 18. GSTO1 aggravates EGFR-TKIs resistance and tumor metastasis via deglutathionylation of NPM1 in lung adenocarcinoma.
    Shen NX; Luo MY; Gu WM; Gong M; Lei HM; Bi L; Wang C; Zhang MC; Zhuang G; Xu L; Zhu L; Chen HZ; Shen Y
    Oncogene; 2024 Aug; 43(33):2504-2516. PubMed ID: 38969770
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PAK1 Is a Novel Therapeutic Target in Tyrosine Kinase Inhibitor-Resistant Lung Adenocarcinoma Activated by the PI3K/AKT Signaling Regardless of EGFR Mutation.
    Wu DW; Wu TC; Chen CY; Lee H
    Clin Cancer Res; 2016 Nov; 22(21):5370-5382. PubMed ID: 27178741
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Transient PI3K inhibition induces apoptosis and overcomes HGF-mediated resistance to EGFR-TKIs in EGFR mutant lung cancer.
    Donev IS; Wang W; Yamada T; Li Q; Takeuchi S; Matsumoto K; Yamori T; Nishioka Y; Sone S; Yano S
    Clin Cancer Res; 2011 Apr; 17(8):2260-9. PubMed ID: 21220474
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.